VAL Valirx Plc

TIDMVAL

RNS Number : 5714Q

ValiRx PLC

21 October 2019

ValiRx Plc

("ValiRx" or the "Company")

Passing of Non-Executive Chairman

London, UK, 21 October 2019: The Board of ValiRx Plc (AIM: VAL), regretfully announce the passing of Non-Executive Chairman Oliver de Giorgio-Miller over the weekend.

The Board offers its deepest sympathies to Oliver's wife and family. Dr Satu Vanikka, ValiRx's CEO, wishes to express her deep regret and shock at such sudden passing of a dear friend and valued colleague.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                 Tel: +44 (0) 20 3008 4416 
                                             www.valirx.com 
 Dr Satu Vainikka, Chief Executive          Tel: +44 (0) 20 3008 4416 
 Tarquin Edwards, Head of Communications.   Tel: +44 (0) 7879 458 
                                             364 
                                             tarquin.edwards@valirx.com 
 
 Cairn Financial Advisers LLP (Nominated    Tel: +44 (0) 20 7213 0880 
  Adviser) 
  Liam Murray / Jo Turner / Ludovico 
  Lazzaretti 
 
 Novum Securities Limited                   Tel: +44 (0) 20 7399 9400 
  Colin Rowbury 
 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOALLFSIIELLFIA

(END) Dow Jones Newswires

October 21, 2019 06:47 ET (10:47 GMT)

Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2023 a Apr 2024